Introduction
============

*Helicobacter pylori* infection affects 20%--50% of the population in the Western world and up to 80% of those in developing countries ([@B1]). *H. pylori* infection causes chronic gastritis and increases the risk of several upper gastrointestinal diseases including peptic ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma ([@B2][@B3]).

In East Asian countries, such as Korea and Japan, where the incidence of gastric cancer is high, eradication of *H. pylori* has been a key strategy in controlling gastric cancer incidence. The incidence of *H. pylori* infection has declined in developed countries, but has remained persistently high in Korea.

The first-line therapy for *H. pylori* infection used world-wide as standard triple therapy (STT) comprising proton pump inhibitor (PPI) and the antibiotics amoxicillin and clarithromycin ([@B4][@B5]). The eradication rate with first-line therapy is disappointingly low (70%--85%). In recent decades, substantial decrease in the efficacy of STT to ≤ 80% has been observed in most countries ([@B5][@B6][@B7]). Thus, the continued use of STT as the first-line regimen has been questioned ([@B8]).

The optimal regimen reflects local preference and experience. Continuous evaluation of treatment outcomes in clinical practice should also be taken into account ([@B9]). There is no large-scale, systematic registry on *H. pylori* eradication in any nation.

The aims of the present study were to obtain a prospective systematic registry database on a nation-wide scale in Korea, and to sample representative Koreans in routine clinical practice to gauge *H. pylori* eradication in Korea. This study focused on epidemiology, efficacy, and safety of the commonly-used treatment regimens to eradicate *H. pylori* in Korea.

Materials and Methods
=====================

Study design
------------

This multicenter, prospective, and observational study (cris.nih.go.kr/KCT0001390) was trial conducted from October 2010 to June 2015.The planned interim analysis was performed in the first half period, from October 2010 to December 2012.

Subjects
--------

Patients who were confirmed to be infected by *H. pylori* and treated for the ensuing infection were enrolled. Patients were not eligible for the study if one of the following criteria was met: known or suspected allergy to PPIs or antibiotics, previous history of gastric surgery, pregnancy or lactation, or therapy with a PPI or antibiotics within 4 weeks of entry.

Evaluation of *H. pylori* infection
-----------------------------------

*H. pylori* infection was diagnosed in patients based on histologic evidence of *H. pylori* by Giemsa staining, positive rapid urease test, positive *H. pylori* culture test, and positive 13C-urea breath test. Patients were diagnosed as infected if any of these tests was positive.

Eradication therapy
-------------------

Investigators prescribed the eradication regimen in accordance with the guidelines established by the Korean College of *Helicobacter* and Upper Gastrointestinal Research group. First-line STT therapy included standard-dose PPI (esomeprazole 40 mg, omeprazole 40 mg, lansoprazole 30 mg, pantoprazole 40 mg, or rabeprazole 20 mg) plus amoxicillin (1,000 mg) and clarithromycin (500 mg) twice a day for 7--14 days. Second-line therapy (PBMT) included the standard-dose twice daily PPI, 120 mg bismuth four times a day, 500 mg metronidazole three times a day, and 500 mg tetracycline four times a day for 7--14 days. Other eradication regimens including sequential therapy (SQ) or concomitant therapy (CT) were also prescribed as first-line or second-line therapy.

To evaluate the success of the eradication therapy, follow-up endoscopy with a rapid urease test and histologic examination, or a 13C-urea breath test was performed at least 4 weeks after the completion of the therapy. The eradication success for *H. pylori* was defined as a negative rapid urease test and histology or a negative 13C-urea breath test, which was confirmed within 6 months after *H. pylori* eradication therapy. Eradication failure was defined as a positive result in any of these tests. Compliance was considered to be satisfactory when drug intake exceeded 80%. Adverse events associated with treatment were also investigated.

Data collection
---------------

The electronic data management system for this study was developed by the Seoul National University Medical Research Collaborating Center using the Pharmacoepidemiology and Clinical Trial Application X (Phacta X) system. Data entry was completed by selecting appropriate icons. Data from clinical information and laboratory test results were entered into a web-based electronic case-reporting form (CRF) following the standard protocol for data-entry ([www.phactax.org](http://www.phactax.org)). The electronic CRF included variables including demographic data (e.g., age, sex, residence, smoking status, alcohol consumption, and comorbidity including hypertension, diabetes, ischemic heart disease, liver cirrhosis, chronic renal failure, and malignancy), diagnostic methods for *H. pylori* infection, treatment indication, regimens, durations, compliance, and treatment-related adverse events. All patients provided written informed consent to participate prior to enrollment. The study was approved by the representative Institutional Review Boards of participating hospitals in Korea.

Statistical analyses
--------------------

Patient characteristics and eradication rate of *H. pylori* were summarized using mean and standard deviation for continuous variables and frequency or percentage for categorical variables. Comparison of continuous variable was performed using Student t-test. Fisher\'s exact test was performed to compare categorical variables. Age was categorized as \< 30, 30--40, 40--50, 50--60, 60--70, or ≥ 70 years. Eradication success rate for the first-line therapy was evaluated by geographic regions. The standardized rates were calculated using patients receiving STT regimens as standard population within the Korean national health insurance database that covered all patients in 2010. Logistic regression analysis was used to examine the associations between *H. pylori* eradication therapy and each of the following factors: age, sex, residence, current smoking, alcohol consumption, medication, previous gastrointestinal disorder, comorbidity, previous *H. pylori* eradication, PPI, duration of treatment, treatment compliance, and treatment-related complications. A multivariate model was constructed using variables with *P* \< 0.2 in univariate logistic regression analysis. SAS version 9.2 (SAS institute Inc., Cary, NC, USA) was used for statistical analysis. Statistical significance was considered for *P* \< 0.05. All *P* values were two-sided.

Ethics statement
----------------

The protocol was approved by the institutional review board at each center (Chung-Ang University Yongsan Hospital, IRB No. 10-031-04-08). All of the patients provided written informed consent for participation in the study.

Results
=======

Baseline demographics
---------------------

Thirty four tertiary and academic hospitals, which were representative of Korean hospitals, prospectively enrolled 5,331 patients. Of them, 3,700 were identified using their eradication results within 6 months after *H. pylori* eradication therapy ([Fig. 1](#F1){ref-type="fig"}). The baseline characteristics of these patients who received first-line eradication therapy are summarized in [Table 1](#T1){ref-type="table"}. Eradication success in first-line therapy was achieved in 2,701 (73.0%) patients. Eradication success declined with age (*P* \< 0.001). However, there was no significant difference (*P* = 0.328) in eradication success between sexes. Concerning regional differences, the eradication rate in Jeju province was the highest (76.1%) and the rate in Chugcheong province was the lowest (60.3%). The difference was significant (*P* \< 0.001) ([Fig. 2](#F2){ref-type="fig"}). There was no significant difference between patients with a current smoking status or currently consuming alcohol and those not currently smoking or drinking (*P* = 0.799 and *P* = 0.261, respectively). The eradication rate in patients who had taken other medications, especially non-steroidal anti-inflammatory drugs, was lower than that in those who had not (*P* \< 0.019). Patients with previous gastrointestinal disorders or comorbidities had significantly lower eradication rates (*P* = 0.018 and *P* = 0.031, respectively). The eradication rate in patients with liver cirrhosis or chronic renal failure was significantly lower than in patients who were free of these diseases (47.0% and 52.9%, respectively). Common adverse events were diarrhea, abdominal pain, nausea, and vomiting ([Table 2](#T2){ref-type="table"}). Diarrhea and abdominal pain were especially common in STT (144 and 35 cases, respectively).

![*Helicobacter pylori* eradication in first-line and second-line therapy. A total of 3,700 patients participated in the study. First-line and second-line therapy overall eradication rate was 73.0% and 84.3%, respectively.](jkms-31-1246-g001){#F1}

###### Baseline characteristics of 3,700 Korean patients who underwent first-line *H. pylori* eradication therapy

![](jkms-31-1246-i001)

  Parameters                                           Total participants with first-line therapy (n = 3,700) No. (%)   Eradication success (n = 2,701) No. (%)   *P* value
  ---------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------- -----------
  Age in years                                                                                                                                                    0.001
   \< 30                                               144 (3.89)                                                       105 (72.92)                               
   30-39                                               322 (8.70)                                                       251 (77.95)                               
   40-49                                               666 (18.0)                                                       511 (76.73)                               
   50-59                                               1,247 (33.7)                                                     917 (73.54)                               
   60-69                                               884 (23.89)                                                      625 (70.7)                                
   ≥ 70                                                437 (11.81)                                                      292 (66.82)                               
  Sex                                                                                                                                                             0.328
   Male                                                2,233 (60.35)                                                    1,643 (73.58)                             
   Female                                              1,467 (39.65)                                                    1,058 (72.12)                             
  Residence                                                                                                                                                       \< 0.001
   Seoul                                               809 (21.86)                                                      592 (73.18)                               
   Gyeonggi                                            692 (18.7)                                                       496 (71.68)                               
   Gangwon                                             93 (2.51)                                                        68 (73.12)                                
   Chungcheong                                         310 (8.38)                                                       187 (60.32)                               
   Gyeongsang                                          1,162 (31.41)                                                    884 (76.08)                               
   Jeolla                                              276 (7.46)                                                       201 (72.83)                               
   Jeju                                                358 (9.68)                                                       273 (76.26)                               
  Current smoking                                                                                                                                                 0.799
   No                                                  2,045 (67.6)                                                     1,486 (72.67)                             
   Yes                                                 795 (26.28)                                                      568 (71.45)                               
  Alcohol consumption                                                                                                                                             0.261
   No                                                  1,637 (54.12)                                                    1,165 (71.17)                             
   Yes                                                 1,209 (39.97)                                                    894 (73.95)                               
  Medication                                                                                                                                                      0.019
   No                                                  1,759 (59.09)                                                    1,285 (73.05)                             
   Yes                                                 1,114 (37.42)                                                    781 (70.11)                               
    Aspirin                                            215 (19.30)                                                      155 (72.09)                               
    Non-steroidal anti-inflammatory drugs              82 (7.36)                                                        46 (59.76)                                
    Antiplatelet/anticoagulation agents, or steroids   41 (3.68)                                                        28 (68.29)                                
  Previous GI disorder                                                                                                                                            0.018
   No                                                  2,315 (77.27)                                                    1,697 (73.3)                              
   Yes                                                 567 (18.93)                                                      382 (67.37)                               
    Peptic ulcer                                       417 (73.54)                                                      276 (66.19)                               
    Others                                             242 (42.68)                                                      158 (65.29)                               
  Comorbidity                                                                                                                                                     0.031
   No                                                  1,743 (58.39)                                                    1,289 (73.95)                             
   Yes                                                 1,162 (38.93)                                                    808 (69.54)                               
    Hypertension                                       721 (62.05)                                                      517 (71.71)                               
    Diabetes                                           315 (27.11)                                                      227 (72.06)                               
    Ischemic heart disease                             62 (5.34)                                                        41 (66.13)                                
    Liver cirrhosis                                    17 (1.46)                                                        8 (47.06)                                 
    Chronic renal failure                              17 (1.46)                                                        9 (52.94)                                 
    Malignancy                                         43 (3.70)                                                        28 (65.12)                                
    Others                                             422 (36.32)                                                      277 (65.64)                               

![Standardized *Helicobacter pylori* eradication rates in first-line therapy according to residence in Korea. The overall eradication rate in seven regions in Korea was 73.0%. Jeju province showed the highest eradication rate in the first-line therapy, whereas Chungcheong province had the lowest (76.1 vs. 60.3, *P* \< 0.001).](jkms-31-1246-g002){#F2}

###### Eradiation success rates and related characteristics of 3,700 Korean patients who underwent the first-line *H. pylori* eradication therapy

![](jkms-31-1246-i002)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  Related parameters                                     Total participants with first-line therapy (n = 3,700)\   Eradication success (n = 2,701)\   *P* value
                                                         No. (%)                                                   No. (%)                            
  ------------------------------------------------------ --------------------------------------------------------- ---------------------------------- -----------
  Indication for eradication                                                                                                                          

   BGU                                                   1,083 (29.27)                                             736 (67.96)                        \< 0.001

   DU                                                    1,057 (28.57)                                             811 (76.73)                        0.001

   BGU+DU                                                1,982 (53.57)                                             1,426 (71.95)                      0.121

   Bleeding peptic ulcer                                 14 (0.38)                                                 12 (85.71)                         0.377

   After endoscopic resection for early gastric cancer   444 (12)                                                  337 (75.9)                         0.142

   Gastric MALT lymphoma                                 39 (1.05)                                                 35 (89.74)                         0.018

   Others                                                870 (23.51)                                               632 (72.64)                        0.787

  Previous *H. pylori* eradication                                                                                                                    \< 0.001

   No                                                    3,495 (94.46)                                             2,581 (73.85)                      

   Yes (within 1 yr)                                     60 (1.62)                                                 33 (5.5)                           

   Yes (before 1 yr)                                     145 (3.92)                                                87 (6.0)                           

    STT                                                  157(76.59)                                                85 (54.14)                         

    PBMT                                                 32 (15.61)                                                26 (81.25)                         

    CT                                                   1 (0.49)                                                  1 (100)                            

    SQ                                                   1 (0.49)                                                  1 (100)                            

    Others                                               14 (6.83)                                                 7 (50)                             

  Regimens                                                                                                                                            \< 0.001

   STT                                                   3,550 (95.95)                                             2,592 (73.01)                      

   PBMT                                                  33 (0.89)                                                 27 (81.82)                         

   CT                                                    31 (0.84)                                                 28 (90.32)                         

   SQ                                                    14 (0.38)                                                 14 (100)                           

   Others                                                72 (1.95)                                                 40 (55.56)                         

  Durations                                                                                                                                           \< 0.001

   7 day                                                 3,310 (89.46)                                             2,435 (73.56)                      

   14 day                                                299 (8.08)                                                216 (72.24)                        

   Others                                                91 (2.46)                                                 50 (54.95)                         

  Compliance                                                                                                                                          \< 0.001

   ≥ 80%                                                 3,608 (97.54)                                             2,653 (73.53)                      

   \< 80%                                                42 (1.14)                                                 22 (52.38)                         

  Complications                                                                                                                                       0.626

   No                                                    2,967 (80.21)                                             2,175 (73.31)                      

   Yes                                                   612 (16.55)                                               437 (71.41)                        

    Abdominal pain                                       73 (11.92)                                                47 (64.38)                         

    Nausea, vomiting                                     126 (20.59)                                               74 (58.73)                         

    Diarrhea                                             215 (35.13)                                               159 (73.95)                        

    Others                                               343 (56.05)                                               249 (72.59)                        

  First-line therapy regimens                                                                                                                         \< 0.001

   STT                                                   3,550 (95.95)                                             2,592 (73.01)                      

   PBMT                                                  33 (0.89)                                                 27 (81.82)                         

   CT                                                    31 (0.84)                                                 28 (90.32)                         

   SQ                                                    14 (0.38)                                                 14 (100)                           

   Others                                                72 (1.95)                                                 40 (55.56)                         

  Second-line therapy regimens                           583 (100)                                                 \-                                 0.327

   PBMT                                                  456 (78.22)                                               391 (85.75)                        

   PAC                                                   10 (1.72)                                                 6 (60)                             

   PTM                                                   33 (5.66)                                                  29 (87.88)                        

   PLM                                                   2 (0.34)                                                  2 (100)                            

   PAM                                                   2 (0.34)                                                  2 (100)                            

   SQ                                                    6 (1.03)                                                  5 (83.33)                          

   Others                                                74 (12.69)                                                60 (81.08)                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------

CT: PPI+AMX+CLA+MTZ; PAC: Proton pump inhibitor+Amoxicillin+Clarithromycin; PAM: Proton pump inhibitor+Amoxicillin+Metronidazole; PBMT: Proton pump inhibitor+Denol+Metronidazole+Tetracyclin; PLM: Proton pump inhibitor+Levofloxacin+Metronidazole; PTM: Proton pump inhibitor+Tetracyclin+Metronidazole; SQ: PPI+AMX -\> PPI+CLA+MTZ; STT: Proton pump inhibitor+Amoxicillin+Clarithromycin.

BGU, benign gastric ulcer including scar; DU, duodenal ulcer including scar; BGU+DU, both benign gastric and duodenal ulcers; CT, Concomitant therapy; SQ, Sequential therapy.

First-line *H. pylori* eradication
----------------------------------

The results of *H. pylori* eradication after the first-line therapy are summarized in [Table 2](#T2){ref-type="table"}. The most common indication for *H. pylori* eradication was benign gastric and duodenal ulcers (53.5%). The eradication rates were significantly different among various gastroduodenal diseases. The eradication rate in patients with gastric MALT lymphoma and benign gastric ulcer was 89.7% and 67.9%, respectively (*P* \< 0.001). The eradication success in naïve patients was higher than that in patients with past history of *H. pylori* eradication treatment (73.8% vs. 58.5%, *P* \< 0.001). The most common first-line therapy was the 7-day PPI-based STT (86.8%). The eradication rates varied among different treatment regimens including STT, CT, PBMT, ST, and others (*P* \< 0.001). The eradication rate with STT therapy was 73.0% compared to 90.3% with CT. The eradication rate of the 7-day treatment was 73.5%. Patients with good compliance to therapy had higher eradication rates than those with poor compliance (73.5% vs. 52.3%, *P* \< 0.001). There was no significant difference in the eradication rate of patients who experienced complications (*P* = 0.626).

*H. pylori* eradication rates according to treatment regimens
-------------------------------------------------------------

The frequency of prescribing regimens in the final analysis (n = 3,700) did not differ significantly from those in the total population (n = 5,331). For the first-line therapy, the frequencies of STT were 3,550/3,700 (95.9%) in the final analysis and 5,099/5,331 (95.6%) in the total analysis. For the second-line therapy, the frequency of PBMT in the final analysis and the total analysis was 456/583 (78.2%) and 531/677 (78.4%), respectively. The *H. pylori* eradication rates in the first-line and second-line therapy according to treatment regimens are summarized in [Table 2](#T2){ref-type="table"}. For patients who had first-line therapy, most commonly STT (95.9%), the overall eradication rate was 73.0%. There was significant difference in the eradication rates according to treatment regimen: 73.0% in STT, 81.8% in PBMT, 100% in SQ, and 90.3% in CT. [Table 3](#T3){ref-type="table"} shows the results of first-line *H. pylori* eradication rate according to the regimen and treatment duration. The most common regimen and treatment duration was STT for 7 days (3,214/3,700, 86.8%), which achieved a 74% eradication success rate. Of the 999 patients whose first-line therapy failed, 583 (58.3%) patients tried the second-line therapy. The overall eradication rate was 84.3%. However, there was no statistically significant difference (*P* = 0.25) in the eradication rate among various treatment regimens ([Table 2](#T2){ref-type="table"}).

###### First-line *Helicobacter pylori* eradication rate according to the regimen and treatment duration

![](jkms-31-1246-i003)

  Duration, day   STT                 PBMT          CT            SQ             Others        Total
  --------------- ------------------- ------------- ------------- -------------- ------------- -------
  7               2,371/3,214 (74%)   24/29 (83%)   3/4 (75%)     0/0 (0%)       37/63 (59%)   3310
  8-13            32/64 (50%)         1/1 (100%)    0/0 (0%)      14/14 (100%)   1/4 (25%)     83
  14              188/268 (70%)       2/3 (67%)     25/26 (96%)   0/0 (0%)       1/2 (50%)     299
  Other           42373               0/0 (0%)      0/1 (0%)      0/0 (0%)       1/3 (33%)     8
  Total           3,550               33            31            14             72            3,700

STT: Proton pump inhibitor+Amoxicillin+Clarithromycin; PBMT: Proton pump inhibitor+Denol+Metronidazole+Tetracyclin; CT: PPI+AMX+CLA+MTZ; SQ: PPI+AMX -\> PPI+CLA+MTZ.

CT, Concomitant therapy; SQ, Sequential therapy.

Factors related to *H. pylori* eradication success
--------------------------------------------------

In univariate analysis, age, residential area, medication, previous gastrointestinal disorder, comorbidity, previous *H. pylori* eradication, PPI, duration of treatment, and compliance to treatment were related to the success of eradication ([Table 4](#T4){ref-type="table"}). After the adjustment for age, residential area, history of *H. pylori* eradication, duration of treatment, and compliance to treatment remained statistically significant. Older age was related to unfavorable outcome (*P* for trend = 0.0543). Chungcheong province showed a decreased success rate; eradication failure was 1.67 times more frequent than in Seoul. Previous history of *H. pylori* eradication treatment increased the failure rate almost twice compared to those without previous treatment. Lower compliance (\< 80%) was related to 2.78 times more treatment failure than patients with high compliance (\> 80%). Treatment duration longer than 7 days did not show any increased success in eradication treatment.

###### Association between the outcome of eradication therapy and risk factors evaluated using logistic regression model

![](jkms-31-1246-i004)

  Variables                            Eradication success rates No. (%) / Total   Univariate analysis     Multivariate analysis                          
  ------------------------------------ ------------------------------------------- ----------------------- ----------------------- ---------- ----------- ----------
  Age in years                         \< 30                                       105 (72.92) / 144       Reference               0.002      Reference   0.009
  30-39                                251 (77.95) / 322                           1.313 (0.835-2.064)     1.337 (0.792-2.257)                            
  40-49                                511 (76.73) / 666                           1.224 (0.813-1.843)     1.236 (0.764-2.000)                            
  50-59                                917 (73.54) / 1,247                         1.032 (0.700-1.522)     0.995 (0.626-1.581)                            
  60-69                                625 (70.7) / 884                            0.896 (0.604-1.331)     0.854 (0.531-1.373)                            
  ≥ 70                                 292 (66.82) / 437                           0.748 (0.492-1.136)     0.753 (0.456-1.243)                            
  Sex                                  Male                                        1,643 (73.58) / 2,233   Reference               0.329      NA          
  Female                               1,058 (72.12) / 1467                        0.929 (0.801-1.077)     NA                                             
  Residence                            Seoul                                       592 (73.18) / 809       Reference               \< 0.001   Reference   \< 0.001
  Gyeonggi                             496 (71.68) / 692                           0.928 (0.739-1.164)     0.859 (0.660-1.116)                            
  Gangwon                              68 (73.12) / 93                             0.997 (0.614-1.618)     1.015 (0.560-1.841)                            
  Chungcheong                          187 (60.32) / 310                           0.557 (0.423-0.734)     0.570 (0.413-0.786)                            
  Gyeongsang                           884 (76.08) / 1,162                         1.166 (0.949-1.432)     1.128 (0.882-1.443)                            
  Jeolla                               201 (72.83) / 276                           0.982 (0.722-1.336)     1.000 (0.712-1.405)                            
  Jeju                                 273 (76.26) / 358                           1.177 (0.882-1.572)     1.294 (0.948-1.766)                            
  Current smoking                      No                                          1,486 (72.67) / 2,045   Reference               0.794      NA          
  Yes                                  568 (71.45) / 795                           0.941 (0.785-1.129)     NA                                             
  NA                                   135 (72.97) / 185                           1.016 (0.724-1.425)     NA                                             
  Alcohol consumption                  No                                          1,165 (71.17) / 1,637   Reference               0.264      NA          
  Yes                                  894 (73.95) / 1,209                         1.150 (0.973-1.359)     NA                                             
  NA                                   129 (72.07) / 179                           1.045 (0.741-1.474)     NA                                             
  Medication                           No                                          1,285 (73.05) / 1,759   Reference               0.022      Reference   0.012
  Yes                                  781 (70.11) / 1,114                         0.865 (0.733-1.021)     0.947 (0.788-1.137)                            
  NA                                   85 (81.73) / 104                            1.650 (0.993-2.744)     2.500 (1.328-4.708)                            
  Previous gastrointestinal disorder   No                                          1,697 (73.30) / 2,315   Reference               0.019      Reference   0.038
  Yes                                  382 (67.37) / 567                           0.752 (0.617-0.917)     0.816 (0.659-1.012)                            
  NA                                   83 (72.81) / 114                            0.975 (0.639-1.488)     0.595 (0.351-1.011)                            
  Comorbidity                          No                                          1,289 (73.95) / 1,743   Reference               0.021      NA          
  Yes                                  808 (69.54) / 1,162                         0.804 (0.682-0.948)     NA                                             
  NA                                   61 (77.22) / 79                             1.194 (0.698-2.041)     NA                                             
  Previous *H. pylori* eradication     No                                          2,581 (73.85) / 3,495   Reference               \< 0.001   Reference   \< 0.001
  Yes (within 1 yr)                    33 (55.0) / 60                              0.433 (0.259-0.723)     0.364 (0.207-0.640)                            
  Yes (before 1 yr)                    87 (60.0)/145                               0.531 (0.378-0.746)     0.627 (0.425-0.925)                            
  Duration in days                     7                                           2,435 (73.56) / 3,310   Reference               \< 0.001   Reference   0.019
  14                                   216 (72.24) / 299                           0.935 (0.718-1.218)     0.918 (0.651-1.295)                            
  Other                                50 (54.95) / 91                             0.438 (0.288-0.667)     0.520 (0.329-0.821)                            
  Compliance                           ≥ 80%                                       2,653 (73.53) / 3,608   Reference               \< 0.001   Reference   \< 0.001
  \< 80%                               22 (52.38) / 42                             0.396 (0.215-0.729)     0.375 (0.196-0.717)                            
  NA                                   25 (51.02) / 49                             0.375 (0.213-0.660)     0.390 (0.189-0.805)                            
  Complication                         No                                          2,175 (73.31) / 2,967   Reference               0.626      NA          
  Yes                                  437 (71.41) / 612                           0.909 (0.749-1.103)     NA                                             
  NA                                   88 (73.33) / 120                            1.001 (0.663-1.513)     NA                                             

NA, not applicable.

Discussion
==========

The current study reports on the establishment and interim results of a nationwide online registry in Korea aimed at tracking the eradication of *H. pylori*. This registry is unique globally. This interim analysis of the 5-year study was planned to review the completeness of the data to date and predict the results at an early stage.

The data supports the evidence that the *H. pylori* eradication rate using standard triple therapy is indeed decreasing and has become sub-optimal in Korea. The eradication rate of first-line therapy has significantly decreased to 73% since 2000, demonstrating a lower than expected efficacy of STT of *H. pylori* infection in Korea. This eradication rate is similar to that in other countries ([@B7][@B10][@B11]). This suggests that alternate regimens including sequential or concomitant therapy are required as soon as possible. This interim analysis underscores the urgency of the current situation in Korea.

Korean guidelines for *H. pylori* infection were formulated in 1998. They state that a definitive indication for *H. pylori* eradication is peptic ulcer including scarring, marginal zone B cell lymphoma (MALT type), and early gastric cancer after endoscopic resection ([@B12]). Since 1998, PPI-based triple therapy has been recommended as the first-line therapy for *H. pylori* eradication in Korea. However, since 2000, the eradication rate has been declining, falling below 80%. The Asia-Pacific Consensus Guidelines have stricter standards that require a success rate of \> 80% in intention-to-treat analysis and \> 90% in per-protocol analysis for a regimen to be considered suitable for first-line eradication therapy ([@B8]). In the present study, the overall eradication rate was only 73% in first-line therapy. Considering the fact that the majority (89.4%) of cases were treated with STT for 7 days, a decline in the eradication rate could imply a serious problem in the management of *H. pylori* infection in Korea. Fortunately, naïve patients had a significantly higher eradication rate than those with previous *H. pylori* infection. These results strongly suggest that more effective first-line therapy is necessary to treat *H. pylori* infection.

In cases where treatment fails, the consensus treatment is one or two weeks of quadruple therapy (PPI + metronidazole + tetracycline + bismuth) ([@B12]). The overall eradication rate of 84.3% in second-line therapy was consistent with the eradication rates observed in previous studies ([@B13]).

Several factors affect the eradication of *H. pylori*. These include antibiotic resistance, geographical area, patient age, smoking status, compliance, duration of therapy, bacterial density, Cag A, gastric acid concentration, individual response to PPI, and the presence of CYP2C19 polymorphism ([@B8]). Of these factors, clarithromycin resistance has been suspected to be the main cause of eradication failure ([@B14][@B15]). In Korea, 5.9% of those treated were resistant to clarithromycin before 2000. However, from 2007--2009, the rate of resistance showed a sharp increase, reaching 38.5% ([@B10][@B16][@B17]). Rates of resistance in other countries are much lower. The discrepancy can be explained by wide international and regional variations in the prevalence of resistance to antibiotics ([@B18][@B19]). In the present study, Jeju province showed the highest eradication rate with STT as the first-line therapy, whereas STT therapy in Chungcheong province had the lowest eradication rate (76.2% vs. 60.3%). Nonetheless, the hypothesis that there are regional differences in Korea is still under debate.

Studies have shown conflicting results in the eradication rate of elderly patients ([@B20][@B21]). In this study, advanced age was positively associated with treatment failure, whereas gender was not associated with treatment failure or eradication rates, which supported the results of a previous study ([@B22]). Some reports assert that smoking can increase treatment failure in *H. pylori* eradication as gastric blood flow and mucus secretion decrease, and as acid secretion increases ([@B23]). However, no significant association between smoking and treatment failure was observed in the present study. A previous report demonstrated an inverse relationship between alcohol consumption and *H. pylori* infection, which indicated alcohol consumption might facilitate eradication ([@B24]). However, no significant relationship between alcohol consumption and eradication failure was observed in this study.

Underlying chronic diseases, such as diabetes mellitus, hypertension, chronic kidney disease, chronic liver disease, and chronic lung disease, have been periodically reported to influence the outcome of *H. pylori* eradication therapy. However, the evidence is limited and the results are inconsistent ([@B25]). In the present study, eradication rates were significantly lower in patients with a history of peptic ulcer and other comorbidities, particularly liver cirrhosis and chronic renal failure. Therefore, this study demonstrates that eradication success is determined by various clinical factors as well as bacterial factors.

Most of recently recommended therapy regimens for *H. pylori* eradication are 7 days in duration. This period is associated with higher compliance and lower medical costs, while maintaining a similar eradication rate to that of longer regimens. Currently, the Korean College of *Helicobacter* and Upper Gastrointestinal Research group recommend a 7-day or 14-day STT. Previous studies in Korea reported that a 7-day STT was not inferior to a 10-day or a 14-day therapy. Recently, more diverse treatment regimens have being administered, including sequential and concomitant therapy, whose satisfactory eradication rates are higher than STT ([@B26][@B27]). Therefore, new strategies to achieve higher *H. pylori* eradication rates are required. Potential approaches in overcoming this problem are patient-tailored sequential or concomitant therapies coupled with prolonged treatment duration in Korea.

Although the number of cases in this study is small, the eradication success with SQ (100%) and CT (90.3%) were significantly (*P* \< 0.001) higher when compared to STT (73.0%). PBMT for 14 days had an eradication success of 81.8%. International guidelines have not incorporated such emerging first-line therapies so far ([@B5][@B28]). However, more recent recommendations suggest that change is likely in the immediate future. A lot of work in developing and validating novel regimens needs to be done before recommending new therapies as first-line therapy against *H. pylori* infection ([@B27][@B29]). Adverse events were reported in 16.5% of patients, mainly mild diarrhea, nausea, and mild vomiting. The types of adverse events or severity were not in particular affected by the differences in the patients\' background.

To date, this is the most comprehensive, systematic, and easily accessible online registration database tracking *H. pylori* eradication in Korea. This registration database will serve as a valuable resource in monitoring antibiotic resistance, *H. pylori* reinfection, and association of *H. pylori* infection with gastric carcinogenesis. This database makes it possible to construct a global network for those working in the field of *H. pylori* control in the future.

In conclusion, our data support the evidence that *H. pylori* eradication rate using STT is decreasing and has become sub-optimal in Korea, suggesting the need for alternate regimens including sequential or concomitant therapy to improve the efficacy of first-line therapy for *H. pylori* infection in Korea.
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